204 related articles for article (PubMed ID: 21115653)
1. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report.
Su JM; Li XN; Thompson P; Ou CN; Ingle AM; Russell H; Lau CC; Adamson PC; Blaney SM
Clin Cancer Res; 2011 Feb; 17(3):589-97. PubMed ID: 21115653
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
Wood PJ; Strong R; McArthur GA; Michael M; Algar E; Muscat A; Rigby L; Ferguson M; Ashley DM
Cancer Chemother Pharmacol; 2018 Sep; 82(3):493-503. PubMed ID: 29987369
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.
Coulter DW; Walko C; Patel J; Moats-Staats BM; McFadden A; Smith SV; Khan WA; Bridges AS; Deal AM; Oesterheld J; Davis IJ; Blatt J
Anticancer Drugs; 2013 Apr; 24(4):415-21. PubMed ID: 23328074
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
Su JM; Murray JC; McNall-Knapp RY; Bowers DC; Shah S; Adesina AM; Paulino AC; Jo E; Mo Q; Baxter PA; Blaney SM
Pediatr Blood Cancer; 2020 Jun; 67(6):e28283. PubMed ID: 32285998
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
7. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Chavez-Blanco A; Segura-Pacheco B; Perez-Cardenas E; Taja-Chayeb L; Cetina L; Candelaria M; Cantu D; Gonzalez-Fierro A; Garcia-Lopez P; Zambrano P; Perez-Plasencia C; Cabrera G; Trejo-Becerril C; Angeles E; Duenas-Gonzalez A
Mol Cancer; 2005 Jul; 4(1):22. PubMed ID: 16001982
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report.
Leary SES; Park JR; Reid JM; Ralya AT; Baruchel S; Wu B; Roberts TPL; Liu X; Minard CG; Fox E; Weigel B; Blaney S
Clin Cancer Res; 2017 Oct; 23(20):6062-6069. PubMed ID: 28751444
[No Abstract] [Full Text] [Related]
9. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
11. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
Kilburn LB; Kocak M; Decker RL; Wetmore C; Chintagumpala M; Su J; Goldman S; Banerjee A; Gilbertson R; Fouladi M; Kun L; Boyett JM; Blaney SM
Neuro Oncol; 2015 Feb; 17(2):303-11. PubMed ID: 25431212
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Fouladi M; Stewart CF; Olson J; Wagner LM; Onar-Thomas A; Kocak M; Packer RJ; Goldman S; Gururangan S; Gajjar A; Demuth T; Kun LE; Boyett JM; Gilbertson RJ
J Clin Oncol; 2011 Sep; 29(26):3529-34. PubMed ID: 21825264
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Munster P; Marchion D; Bicaku E; Lacevic M; Kim J; Centeno B; Daud A; Neuger A; Minton S; Sullivan D
Clin Cancer Res; 2009 Apr; 15(7):2488-96. PubMed ID: 19318486
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE
J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.
Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G
J Neurooncol; 2018 May; 138(1):199-207. PubMed ID: 29427149
[TBL] [Abstract][Full Text] [Related]
18. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients.
Taylor LM; Farzam F; Cook AM; Lewis DA; Baumann RJ; Kuhn RJ
Pharmacotherapy; 2007 Apr; 27(4):519-25. PubMed ID: 17381378
[TBL] [Abstract][Full Text] [Related]
20. Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
Ben Mahmoud L; Hakim A; Ghozzi H; Atheymen R; Sahnoun Z; Zeghal K
Rev Neurol (Paris); 2017 Mar; 173(3):159-163. PubMed ID: 28320517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
